Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

2017-10-22 20:10:13 | BioPortfolio


This is the first study to test Sym021 in humans. The primary purpose of this study is to see if Sym021 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.


This study will evaluate the preliminary safety, tolerability, and dose-limiting toxicities (DLTs) of Sym021, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) . The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of Sym021 when administered once every 2 weeks (Q2W) by 30-minute intravenous (IV) infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available. If an MTD is not identified, a maximum administered dose (MAD) will be determined.

Sym021 will be given to patients in escalating dose cohorts; each patient will be given one fixed dose level. There will be a minimum of 3 patients per dose cohort, assuming approximately 3 dose cohorts to be evaluated to establish the MTD and/or RP2D dose. Any cohort will be expanded to 6 patients in the event of a Cycle 1 DLT in any of the initial 3 patients. A minimum of 6 patients are to be treated at the MTD and/or RP2D dose; expansion of this cohort (or any other) up to 12 patients may be considered to further evaluate tolerability.

In addition, there is potential for entry of additional patients for the following reasons:

- To ensure sufficient evaluable patients by adding an additional patient to a cohort (e.g. increase a 3-patient cohort to 4 patients, or a 6-patient cohort to 7 patients).

- To expand a lower dose cohort(s) if an initially identified MTD and/or RP2D is subsequently determined not to be tolerated either with single or repeated cycles of therapy.

- To add and evaluate a previously unexamined intermediate dose level(s) to further characterize safety and tolerability, if indicated.

Study Design


Metastatic Cancer




South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids
United States


Not yet recruiting


Symphogen A/S

Results (where available)

View Results


Published on BioPortfolio: 2017-10-22T20:10:13-0400

Clinical Trials [3716 Associated Clinical Trials listed on BioPortfolio]

Advanced Breast Cancer and Lifestyle Exercise Study

About 5% of breast cancers are metastatic at diagnosis and 20-30% of localized breast cancer become secondarily metastatic.Thanks to recent therapeutic advances, the median survival ranges...

Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer and triple negative breast cancer. PMD-026 is a targeted oral agent de...

First Line Metastatic Breast Cancer Treatment (ESMERALDA)

The efficacy of eribulin is now well known in metastatic breast cancer. Furthermore, a phase III combine study ( chemo + bev)in metastatic first line shown a gain in PFS with no extra tox...

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA), [18F]DCFPyL (DCFPyL) PET/CT (or PET/MRI imaging ...

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

Patients with metastatic prostate cancer can undergo MRI-guided prostate Stereotactic body radiation therapy (SBRT) without significant adverse events, similar to what has been reported fo...

PubMed Articles [14126 Associated PubMed Articles listed on BioPortfolio]

A case of metastatic prostate cancer treated with metastasectomy.

In general, metastatic prostate cancer is managed medically. Here we present a patient with metastatic prostate cancer who was treated by surgical resection in addition to medical therapies. Local the...

Cancer Genome Evolutionary Trajectories in Metastasis.

Metastatic cancer is a major cause of death and remains largely incurable. A better understanding of metastasis is therefore desperately needed to improve prognosis for late-stage disease. Here we sur...

Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer.

Electronic medical records (EMRs) and population-based cancer registries contain information on cancer outcomes and treatment, yet rarely capture information on the timing of metastatic cancer recurre...

Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer.

Differences between the features of primary cancer and matched metastatic cancer have recently drawn attention in research. This study investigated the concordance in microsatellite instability (MSI) ...

The Two Faces of Relaxin in Cancer: Antitumor or Protumor?

The liver is one of the most common sites of metastatic disease from a variety of primary tumors including colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), melanoma, breast cancer, and lung...

Medical and Biotech [MESH] Definitions

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

Mucocellular carcinoma of the ovary, usually metastatic from the gastrointestinal tract, characterized by areas of mucoid degeneration and the presence of signet-ring-like cells. It accounts for 30%-40% of metastatic cancers to the ovaries and possibly 1%-2% of all malignant ovarian tumors. The lesions may not be discovered until the primary disease is advanced, and most patients die of their disease within a year. In some cases, a primary tumor is not found. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1685)

An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.

More From BioPortfolio on "Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas"

Quick Search

Relevant Topic

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Searches Linking to this Trial